Taking pharmacologic management of COPD into the future

Winfred Manda, Stephen I. Rennard

Research output: Contribution to journalReview article

Abstract

Chronic obstructive pulmonary disease (COPD) is disabling and often fatal, and acute exacerbations are a primary reason for ICU admission and use of emergency department services. Prompt restoration of airflow is imperative. A primary challenge is coming up with an individualized management strategy that reduces risk factors, is useful when a patient's symptoms are stable, and also helps reduce episodes of exacerbations. Current pharmacologic therapies, which have been based on objective improvements in expiratory airflow, include inhaled bronchodilators such as the anticholinergic ipratropium, short- and long-acting β2-agonists, and theophylline. Tiotropium, which is not yet available in the United States, may become a useful addition to the therapeutic choices. Novel phosphodiesterase 4 inhibitors, including roflumilast, piclamilast, and cilomilast, are being investigated. As pathophysiologic mechanisms become clearer, combining drugs that have different mechanisms and durations of action may prove key in lever-aging the greatest symptom control with the fewest side effects. Giving a first-generation β2-adrenergic agonist, such as albuterol, for example, together with an antimuscarinic agent is pharmacologically reasonable from the standpoints of both efficacy and safety.

Original languageEnglish (US)
Pages (from-to)33-42
Number of pages10
JournalJournal of Critical Illness
Volume18
Issue number1
StatePublished - Jan 1 2003

Fingerprint

Chronic Obstructive Pulmonary Disease
Phosphodiesterase 4 Inhibitors
Ipratropium
Pulmonary Ventilation
Adrenergic Agonists
Muscarinic Antagonists
Albuterol
Bronchodilator Agents
Cholinergic Antagonists
Theophylline
Hospital Emergency Service
Safety
Therapeutics
Pharmaceutical Preparations
Cilomilast
piclamilast
Roflumilast
Tiotropium Bromide

Keywords

  • Bronchodilators
  • Bronchodilatory responses to tiotropium
  • COPD severity classification
  • Clinical Conclusions
  • Corticosteroids
  • Mechanisms of pharmacologic action
  • Staged treatment

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Taking pharmacologic management of COPD into the future. / Manda, Winfred; Rennard, Stephen I.

In: Journal of Critical Illness, Vol. 18, No. 1, 01.01.2003, p. 33-42.

Research output: Contribution to journalReview article

Manda, W & Rennard, SI 2003, 'Taking pharmacologic management of COPD into the future', Journal of Critical Illness, vol. 18, no. 1, pp. 33-42.
Manda, Winfred ; Rennard, Stephen I. / Taking pharmacologic management of COPD into the future. In: Journal of Critical Illness. 2003 ; Vol. 18, No. 1. pp. 33-42.
@article{6c91b0cf831145cf9dea9930df583ea4,
title = "Taking pharmacologic management of COPD into the future",
abstract = "Chronic obstructive pulmonary disease (COPD) is disabling and often fatal, and acute exacerbations are a primary reason for ICU admission and use of emergency department services. Prompt restoration of airflow is imperative. A primary challenge is coming up with an individualized management strategy that reduces risk factors, is useful when a patient's symptoms are stable, and also helps reduce episodes of exacerbations. Current pharmacologic therapies, which have been based on objective improvements in expiratory airflow, include inhaled bronchodilators such as the anticholinergic ipratropium, short- and long-acting β2-agonists, and theophylline. Tiotropium, which is not yet available in the United States, may become a useful addition to the therapeutic choices. Novel phosphodiesterase 4 inhibitors, including roflumilast, piclamilast, and cilomilast, are being investigated. As pathophysiologic mechanisms become clearer, combining drugs that have different mechanisms and durations of action may prove key in lever-aging the greatest symptom control with the fewest side effects. Giving a first-generation β2-adrenergic agonist, such as albuterol, for example, together with an antimuscarinic agent is pharmacologically reasonable from the standpoints of both efficacy and safety.",
keywords = "Bronchodilators, Bronchodilatory responses to tiotropium, COPD severity classification, Clinical Conclusions, Corticosteroids, Mechanisms of pharmacologic action, Staged treatment",
author = "Winfred Manda and Rennard, {Stephen I.}",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "18",
pages = "33--42",
journal = "Journal of Critical Illness",
issn = "1040-0257",
publisher = "Cliggott Publishing Co.",
number = "1",

}

TY - JOUR

T1 - Taking pharmacologic management of COPD into the future

AU - Manda, Winfred

AU - Rennard, Stephen I.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Chronic obstructive pulmonary disease (COPD) is disabling and often fatal, and acute exacerbations are a primary reason for ICU admission and use of emergency department services. Prompt restoration of airflow is imperative. A primary challenge is coming up with an individualized management strategy that reduces risk factors, is useful when a patient's symptoms are stable, and also helps reduce episodes of exacerbations. Current pharmacologic therapies, which have been based on objective improvements in expiratory airflow, include inhaled bronchodilators such as the anticholinergic ipratropium, short- and long-acting β2-agonists, and theophylline. Tiotropium, which is not yet available in the United States, may become a useful addition to the therapeutic choices. Novel phosphodiesterase 4 inhibitors, including roflumilast, piclamilast, and cilomilast, are being investigated. As pathophysiologic mechanisms become clearer, combining drugs that have different mechanisms and durations of action may prove key in lever-aging the greatest symptom control with the fewest side effects. Giving a first-generation β2-adrenergic agonist, such as albuterol, for example, together with an antimuscarinic agent is pharmacologically reasonable from the standpoints of both efficacy and safety.

AB - Chronic obstructive pulmonary disease (COPD) is disabling and often fatal, and acute exacerbations are a primary reason for ICU admission and use of emergency department services. Prompt restoration of airflow is imperative. A primary challenge is coming up with an individualized management strategy that reduces risk factors, is useful when a patient's symptoms are stable, and also helps reduce episodes of exacerbations. Current pharmacologic therapies, which have been based on objective improvements in expiratory airflow, include inhaled bronchodilators such as the anticholinergic ipratropium, short- and long-acting β2-agonists, and theophylline. Tiotropium, which is not yet available in the United States, may become a useful addition to the therapeutic choices. Novel phosphodiesterase 4 inhibitors, including roflumilast, piclamilast, and cilomilast, are being investigated. As pathophysiologic mechanisms become clearer, combining drugs that have different mechanisms and durations of action may prove key in lever-aging the greatest symptom control with the fewest side effects. Giving a first-generation β2-adrenergic agonist, such as albuterol, for example, together with an antimuscarinic agent is pharmacologically reasonable from the standpoints of both efficacy and safety.

KW - Bronchodilators

KW - Bronchodilatory responses to tiotropium

KW - COPD severity classification

KW - Clinical Conclusions

KW - Corticosteroids

KW - Mechanisms of pharmacologic action

KW - Staged treatment

UR - http://www.scopus.com/inward/record.url?scp=0037241522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037241522&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0037241522

VL - 18

SP - 33

EP - 42

JO - Journal of Critical Illness

JF - Journal of Critical Illness

SN - 1040-0257

IS - 1

ER -